News & Updates

Short-term tumour necrosis factor (TNF) inhibition with adalimumab falls short of producing improvements in patients with radiographic knee osteoarthritis, according to the proof-of-concept OKINADA trial presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.

Uncontrolled diabetes among older adults with preclinical heart failure (HF) stages appears to increase the risk of HF progression, suggests a study.

A study of Thai patients with impaired glucose tolerance (IGT) has found only a slight reduction in weight among its participants, highlighting the need for more intensive efforts with structured lifestyle programs to prevent diabetes.

The investigational drug ABX464, also known as obefazimod, helps reduce disease activity in patients with rheumatoid arthritis (RA), according to the results of a phase II trial. The 50-mg dose is well tolerated, while the higher dose is associated with mild-to-moderate adverse effects resulting in treatment discontinuation.

Treatment with BI 1015550, a novel investigational phosphodiesterase 4 (PDE4) inhibitor, slows lung function decline in patients with idiopathic pulmonary fibrosis (IPF) with or without background antifibrotic therapy, according to a 12-week phase II trial data presented at ATS 2022.